Jane Street Group LLC Lowers Holdings in Cabaletta Bio, Inc. (NASDAQ:CABA)

Jane Street Group LLC reduced its position in Cabaletta Bio, Inc. (NASDAQ:CABA) by 48.8% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 157,702 shares of the company’s stock after selling 150,313 shares during the quarter. Jane Street Group LLC owned about 0.32% of Cabaletta Bio worth $744,000 as of its most recent filing with the SEC.

Other large investors also recently bought and sold shares of the company. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Cabaletta Bio during the third quarter worth about $32,000. Point72 DIFC Ltd purchased a new stake in Cabaletta Bio in the 3rd quarter valued at approximately $33,000. China Universal Asset Management Co. Ltd. increased its position in Cabaletta Bio by 65.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,395 shares of the company’s stock worth $44,000 after purchasing an additional 3,724 shares during the period. Intech Investment Management LLC purchased a new position in shares of Cabaletta Bio during the 3rd quarter worth approximately $67,000. Finally, GSA Capital Partners LLP acquired a new stake in shares of Cabaletta Bio in the 3rd quarter valued at approximately $127,000.

Cabaletta Bio Trading Up 2.6 %

Shares of CABA opened at $2.33 on Friday. Cabaletta Bio, Inc. has a 12-month low of $1.76 and a 12-month high of $26.35. The stock has a market cap of $113.88 million, a P/E ratio of -1.08 and a beta of 2.37. The company has a 50-day moving average of $3.16 and a two-hundred day moving average of $4.87.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on CABA. Evercore ISI lowered Cabaletta Bio from an “outperform” rating to an “inline” rating and dropped their price objective for the stock from $15.00 to $6.00 in a report on Friday, December 20th. William Blair reaffirmed an “outperform” rating on shares of Cabaletta Bio in a research note on Monday, November 18th. TD Cowen upgraded shares of Cabaletta Bio to a “strong-buy” rating in a report on Friday, November 29th. Wells Fargo & Company downgraded shares of Cabaletta Bio from an “overweight” rating to an “equal weight” rating and decreased their price objective for the stock from $12.00 to $6.00 in a report on Thursday, December 19th. Finally, UBS Group initiated coverage on shares of Cabaletta Bio in a report on Thursday, October 10th. They issued a “buy” rating and a $10.00 target price for the company. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Cabaletta Bio currently has a consensus rating of “Buy” and a consensus price target of $24.38.

Cabaletta Bio Profile

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.